BMY vs. JNJ, ABBV, MRK, PFE, ZTS, RPRX, JAZZ, CORT, PRGO, and SUPN
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Bristol-Myers Squibb vs.
Johnson & Johnson (NYSE:JNJ) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, community ranking, media sentiment and valuation.
Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.0%. Bristol-Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 4.1%. Johnson & Johnson pays out 74.6% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -56.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 63 consecutive years and Bristol-Myers Squibb has raised its dividend for 17 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
Johnson & Johnson has a net margin of 18.20% compared to Bristol-Myers Squibb's net margin of -18.53%. Johnson & Johnson's return on equity of 34.24% beat Bristol-Myers Squibb's return on equity.
Johnson & Johnson has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
Johnson & Johnson currently has a consensus price target of $171.33, indicating a potential upside of 4.68%. Bristol-Myers Squibb has a consensus price target of $57.86, indicating a potential downside of 4.70%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts plainly believe Johnson & Johnson is more favorable than Bristol-Myers Squibb.
In the previous week, Johnson & Johnson had 54 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 105 mentions for Johnson & Johnson and 51 mentions for Bristol-Myers Squibb. Bristol-Myers Squibb's average media sentiment score of 1.49 beat Johnson & Johnson's score of 1.29 indicating that Bristol-Myers Squibb is being referred to more favorably in the news media.
Johnson & Johnson received 34 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. However, 66.10% of users gave Bristol-Myers Squibb an outperform vote while only 64.93% of users gave Johnson & Johnson an outperform vote.
69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Johnson & Johnson beats Bristol-Myers Squibb on 16 of the 22 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
This page (NYSE:BMY) was last updated on 3/24/2025 by MarketBeat.com Staff
